More than just life and death: advances in imaging and analysis for 3D-bioprinted tissues.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-06-11 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1600077

Erin R Spiller, Daniela F Duarte Campos

引用次数: 0

Abstract

3D bioprinting is a fast-growing field with applications in both microphysiological systems and tissue engineering. However, the qualifications and definitions of success for 3D-bioprinted products are insufficient. We can further our characterization of 3D-bioprinting methods and finished products using new imaging techniques and analysis methods, including the use of AI tools. This multi-faceted approach can deepen our understanding of valuable technology by examining the effects of 3D bioprinting on cell identity, behavior and organelles. Defining a successful 3D-bioprinted product in addition to viability is crucial in the push toward using these models for drug screening or disease modeling, where robust and high-quality systems are required for meaningful data output.

查看原文本刊更多论文

不仅仅是生与死：3d生物打印组织成像和分析的进步。

生物3D打印是一个快速发展的领域，在微生理系统和组织工程中都有应用。然而，3d生物打印产品成功的资格和定义是不够的。我们可以使用新的成像技术和分析方法，包括使用人工智能工具，进一步表征3d生物打印方法和成品。通过研究3D生物打印对细胞身份、行为和细胞器的影响，这种多方面的方法可以加深我们对有价值技术的理解。在推动将这些模型用于药物筛选或疾病建模的过程中，除了可行性之外，定义一个成功的3d生物打印产品是至关重要的，因为这些模型需要强大和高质量的系统来进行有意义的数据输出。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.